Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cibenzoline→

Cibenzoline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
53267-01-9
Molecular formula
C18H18N2
Molecular weight
262.3 g/mol
Drug class
Class Ic antiarrhythmic (also classified as class Ia in some references)sodium-channel blocker
Mechanism of action
Blocks fast cardiac sodium channels and slows conduction. It also has effects on L-type calcium and potassium channels and antimuscarinic activity; electrophysiological effects and class designation vary with the classification framework.
Indications / reported uses
  • Treatment of selected tachyarrhythmias, including recent-onset atrial fibrillation and other supraventricular or ventricular tachyarrhythmias in countries where authorised; use requires ECG and structural-heart-disease assessment

Sources: European Heart Rhythm Association practical compendium (2025) · JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cibenzoline Environmental Risk Assessment (ERA) (the Cibenzoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.